AllSci News
Beeline Medicines debuts with USD 300m Series A and BMS autoimmune therapies
Beeline Medicines Corporation, a clinical-stage biotechnology company headquartered in Stamford, Connecticut, has publicly debuted with a USD 300 million...
Terremoto closes USD 108 million Series C financing for AKT1 inhibitors
Terremoto Biosciences, a clinical-stage biotechnology company based in South San Francisco, has closed a USD 108 million Series C financing round to advance...
Telix Pharma raises USD 600m in convertible bond offering
Australia-based Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced a USD 600 million convertible bond offering on April 14, 2026, executing a...
Spiral Therapeutics closes USD 27m Series B to advance inner ear disorder treatments
Spiral Therapeutics, a clinical-stage biotechnology company based in South San Francisco focused on inner ear disorders, has closed a USD 27 million Series...
J&J's Q1'25 Earnings Call: Icotyde and JNJ-4804's immunology pathway in focus
J&J's ICOTYDE and JNJ-4804 Emerge as Central Pipeline Signals in JNJ Q1 2026 Earnings
Arbutus Biopharma's imdusiran hepatitis B therapy takes FDA Fast Track status
Arbutus Biopharma announced on April 15, 2026 that the US FDA granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B...
Immorna's posts early positive data for in vivo CAR-T in systemic sclerosis
Immorna, a Hangzhou-based clinical-stage biotechnology company, reported early clinical data for JCXH-213, its CD19-targeted in vivo CAR-T candidate, in a...
Revolution Medicines raises USD 2b in concurrent public offerings
Revolution Medicines, Inc. (Nasdaq: RVMD), a Redwood City, California-based oncology company focused on RAS-addicted cancer therapies, announced concurrent...
Traws Pharma raises USD 60m in private placement financing
Traws Pharma, Inc. (Nasdaq: TRAW), a clinical-stage biopharmaceutical company based in Newtown, Pennsylvania, announced a private placement financing of up...
Obsidian Therapeutics gains Nasdaq listing via all-stock merger with Galera Therapeutics and USD 350m PIPE
Private US-based Obsidian Therapeutics has announced a definitive all-stock merger agreement with compatriot firm Galera Therapeutics (OTC: GRTX),...
Amgen terminates Phase I trial of AMG 378 in strategic decision
Amgen Terminates Phase I Trial of AMG 378 Before Primary Completion
Kazia Therapeutics acquires SETDB1 inhibitor platform from QIMR Berghofer
A preclinical bicyclic peptide targeting a disease-associated nuclear SETDB1 complex sits at the center of an in-licensing agreement announced April 13...
Eli Lilly acquires dual-payload ADC platform from CrossBridge Bio for up to USD 300m
Eli Lilly Acquires Dual-Payload ADC Platform for Up to USD 300 Million via CrossBridge Bio Deal
Mesoblast takes CAR-MSC platform license from Mayo Clinic spinout
Australia-based Mesoblast Limited (NASDAQ: MESO; ASX: MSB) has acquired an exclusive worldwide license to a patented chimeric antigen receptor technology...
Hengrui's obesity 'New Co.' Kailera Therapeutics targeting USD 500m Nasdaq IPO
Kailera Therapeutics (Nasdaq: KLRA) filed for an initial public offering of 33,333,334 shares of common stock at a price range of $14.00 to $16.00 per...
The AllSci Brief
Free, systematic R&D and deal news. Daily.